

**FREEDOM OF INFORMATION SUMMARY
FOR
SYNOVEX[®] C AND SYNOVEX[®] S
(ESTRADIOL BENZOATE & PROGESTERONE)**

1. GENERAL INFORMATION

NADA Number: 9-576

Sponsor: Fort Dodge Animal Health
9401 Indian Creek Parkway
Overland Park, KS 66210

Generic Name: Estradiol benzoate and progesterone

Trade Names: Synovex[®] C and Synovex[®] S

Marketing Status: Over the Counter (OTC)

Effect of Supplement: This supplement provides for the implantation of Synovex[®] C in steers fed in confinement for slaughter when used as part of a reimplant program where Synovex[®] S is implanted at approximately day 70 after the initial implantation of Synovex[®] C.

2. INDICATIONS FOR USE

Synovex[®] C

Synovex[®] C is recommended for use in suckling beef calves up to approximately 400 pounds of body weight. Synovex[®] C is also recommended for improvement in rate of weight gain in steers weighing greater than 400 pounds and fed in confinement for slaughter when used as part of a re-implant program in which an initial Synovex[®] C implant is followed at approximately 70 days by Synovex[®] S.

Synovex[®] S

For increased rate of weight gain and improved feed efficiency. For additional improvement in rate of weight gain in steers fed in confinement for slaughter, Synovex[®] S may be used as part of a re-implant program where an initial Synovex[®] C or Synovex[®] S implant is followed by Synovex[®] S at approximately 70 days.

3. DOSAGE FORM(S), ROUTES(S) OF ADMINISTRATION AND RECOMMENDED DOSAGE

Dosage form: Implantation.

Route of administration: Subcutaneous implantation on the posterior aspect of the middle one-third of the ear by means of an implant gun.

Recommended Dosage: *Synovex*[®] C: One implant containing 100 mg progesterone and 10 mg estradiol benzoate. *Synovex*[®] S: One implant containing 200 mg progesterone and 20 mg estradiol benzoate. May be re-implanted at approximately 70 days.

4. EFFECTIVENESS

Effectiveness is established by data in the parent application. Therefore, no further studies were required.

5. TARGET ANIMAL SAFETY

Target animal safety is established by data in the parent application. Therefore, no further studies were required.

6. HUMAN SAFETY

Human safety is established by data in the parent application. Therefore, no further studies were required.

7. AGENCY CONCLUSIONS

Adequate data demonstrates the safe and effective use of *Synovex*[®] C and *Synovex*[®] S for additional improvement in rate of weight gain when administered to steers fed in confinement for slaughter.

Under the Center's supplemental approval policy (21 CFR 514.106(b)(2)), this is a Category II change providing for the implantation of *Synovex*[®] C in steers fed in confinement for slaughter when used as part of a reimplant program where *Synovex*[®] S is implanted at approximately day 70 after the initial implantation of *Synovex*[®] C. The approval of this change is not expected to have any adverse effect on the safety or effectiveness of this new animal drug. Accordingly, this approval did not require a reevaluation of the safety and effectiveness data in the parent application.

8. LABELING

Two (2) pages of labeling are attached as follows:

1. Synovex[®] S 10 Cartridge Box Label
2. Synovex[®] C 10 Cartridge Box Label

cc: HFV-199, NADA 9-576 Orig.
HFV-2 (Mailing List)
HFV-12 (FOI Staff)
HFV-102 (GADQC Reserve Copy)
HFV-102 Green Book (NTurner)
HFA-305 (Dockets Management Branch)
HFR-MA350 (District Office Copy)

Sponsor's courtesy copy
ELMonk, HFV-126:5/13/98

ec: CVM Records\\ONADE\\N009576\C0130foi.sum